Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T. Shaw, D. Ross Camidge, Justin F. Gainor et al.|The Lancet Oncology|2011Cited by 903
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCS.-H.I. Ou, Gregory J. Riely, Pasi A. Jänne et al.|Annals of Oncology|2014Cited by 221